1. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S et al (2007) Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31:1345–50
2. Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K et al (2008) A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 1:429–34
3. Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Mori-Iwamoto S et al (2011) KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy 57:12–6
4. Kuramitsu Y, Wang Y, Taba K, Suenaga S, Ryozawa S, Kaino S et al (2012) Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res 32:2295–9
5. Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ et al (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879–84